Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

6.420 +1.920 (+42.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,417,959
Open 5.280
Bid (Size) 6.170 (10)
Ask (Size) 6.200 (2)
Prev. Close 4.500
Today's Range 4.990 - 6.690
52wk Range 2.235 - 18.14
Shares Outstanding 42,052,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
The market is filled with gapping stocks in Friday's session.
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill

Performance

YTD
+10.1%
+10.1%
1 Month
+54.7%
+54.7%
3 Month
+86.6%
+86.6%
6 Month
+14.6%
+14.6%
1 Year
-63.8%
-63.8%

More News

Read More
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
Via Benzinga
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
Via Benzinga
These stocks that are showing activity before the opening bell on Friday.
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
These stocks are moving in today's after hours session
Via Chartmill
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Via Benzinga
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
Via Benzinga

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 6.420
When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 08/01/25 04:00 PM ET
What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 269.98M
How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
4D Molecular Therapeutics, Inc. - Common Stock has 270M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.